Recombinant RSV B1 expressing eGFP as a reporter gene

The inventors have created a reverse genetics system for RSV strain B1 of antigenic subgroup B encoding a replication-competent recombinant RSV that contains a codon-optimized G ORF and expresses enhanced green fluorescence protein (GFP). There are two antigenic subgroups of RSV, subgroups A and B, and most of the available information and reagents are for subgroup A. Immunity against either subgroup has reduced effectiveness in restricting the heterologous subgroup, suggesting that an effective RSV vaccine might need to contain both subgroups.

Hybridoma cell lines producing antibodies to RSV NS1

This technology provides a new set of hybridoma cell lines each expressing a single monoclonal antibody against human respiratory syncytial virus (RSV) nonstructural protein 1 (NS1). These antibodies have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow cytometry. The various antibodies can vary in their efficiency in each of these assays.

Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development

The Huh-7 cell line underwent a detailed sub-cloning process to enhance its effectiveness for Hepatitis E Virus (HEV) infection studies. This involved diluting and culturing cells in 96-well plates until confluent monolayers formed, followed by selection and expansion of the most suitable cells. The sub-clone S10-3, derived from this process, was identified as the most efficient for transfection and infection by HEV.

Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery

This technology includes the NeurEx® mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app's robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments.

Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes

The technology involves the genetic engineering of Respiratory Syncytial Virus (RSV) to express two additional genes, green fluorescent protein (GFP) and Renilla luciferase, from different positions within the viral genome. GFP serves as a visual marker for RSV infection, allowing researchers to monitor and track infected cells using fluorescence microscopy, while luciferase functions as a highly sensitive reporter gene that enables quantitative assessment of viral replication through enzymatic assays.

Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2

In this technology, researchers have engineered a modified version of Respiratory Syncytial Virus (RSV) strain A2 using reverse genetics to incorporate green fluorescent protein (GFP) into the first-gene position. This genetic modification allows for the efficient monitoring of RSV infection and the screening of potential chemical inhibitors. The GFP expression can be easily detected through fluorescence microscopy in live or fixed cells, providing a sensitive tool for both research and drug discovery.

Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)

The noroviruses (known as "Norwalk-like viruses") are associated with an estimated 23,000,000 cases of acute gastroenteritis in the United States each year. Norovirus illness often occurs in outbreaks, affecting large numbers of individuals, illustrated recently by well-publicized reports of gastroenteritis outbreaks on several recreational cruise ships and in settings such as hospitals and schools. Norovirus disease is clearly important in terms of medical costs and missed workdays, and accumulating data support its emerging recognition as important agents of diarrhea-related morbidity.

SARS-CoV-2 Virus Specimen and Material Sharing

FLC logo

The Centers for Disease Control and Prevention (CDC) and the National Institute for Allergy and Infectious Diseases (NIAID) have been rewarded for their partnership from the 2021 Federal Laboratory Consortium (FLC) awards. The CDC and NIAID had already developed a new approach to sharing samples during a Public Health Emergency of International Concern (PHEIC) during the Zika pandemic, which enabled them to respond quickly and efficiently to access and share samples of SARS-CoV-2 early in the outbreak.

Rapid Sharing of SARS-CoV-2 Prefusion Stabilized Spike Proteins and Plasmids

FLC logo

Within hours of the public release of the viral genome sequence, scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) and their collaborators engineered a key protein from SARS-CoV-2, the virus that causes COVID-19, to enable its study as a vaccine candidate and for research applications.

Subscribe to Research Materials